[Progress in the clinical cure of the population of inactive hepatitis B surface antigen carriers].
Zhonghua Gan Zang Bing Za Zhi
; 31(12): 1336-1339, 2023 Dec 20.
Article
en Zh
| MEDLINE
| ID: mdl-38253081
ABSTRACT
The population of inactive HBsAg carriers (IHCs) is enormous, and it is often overlooked because of the insidious progression and mild severity of the disease. With the continuous enrichment and consolidation of research evidence, the population of IHC has obtained a high clinical cure rate through a treatment strategy based on pegylated interferon α and a stronger treatment intention. This article reviews the definition and treatment recommendations of IHCs in current domestic and international guidelines, as well as the disease progression and clinical cure research progress, so as to provide a reference and basis for scientific management and rational therapeutics.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Interferón-alfa
/
Antígenos de Superficie de la Hepatitis B
Tipo de estudio:
Guideline
Idioma:
Zh
Año:
2023
Tipo del documento:
Article